Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daptomycin versus semi-synthetic penicillins or vancomycin in elderly patients with complicated skin and soft tissue infections
2009-014391-22Phase 4Completed
- Sponsor
- Novartis
- Start
- Dec 2009
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of daptomycin, vancomycin, Oxacillin and flucloxacillin in skin and soft tissue infections (SSTIs) (2 arms), sponsored by Novartis. Primary endpoint: Clinical success at test of cure. Started Dec 2009; status: completed.
02
Drugs
daptomycinvancomycinOxacillinflucloxacillin
03
Conditions
skin and soft tissue infections (SSTIs)
Beyond the preview
Go deeper on 2009-014391-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014391-22.